Table 1.
Baseline characteristics
| Characteristics | Cabazitaxel (n = 115) | Abiraterone or enzalutamide (n = 107) | Total (N = 222) |
|---|---|---|---|
| Median age, years | 70 | 70 | 70 |
| Aged ≥75 years, n (%) | 42 (36.5) | 27 (25.2) | 69 (31.1) |
| ECOG PS 0 or 1, n (%) | 111 (96.5) | 104 (97.2) | 215 (96.8) |
| Liver or lung metastases, n (%) | 18 (15.7) | 20 (18.7) | 38 (17.1) |
| Median PSA, ng/mL | 61.02 | 68.04 | 62.7 |
| Median neutrophil count, mm3 | 4500 | 4660 | 4540 |
| Median haemoglobin, g/L | 121 | 121 | 121 |
| Median alkaline phosphatase, IU/L | 125 | 115.5 | 120.5 |
| Median LDH, IU/L | 241.5 | 251 | 243 |
| Type of progression at trial entry, n (%) | |||
| PSA only (no radiological progression, no pain) | 11 (9.6) | 9 (8.4) | 20 (9.0) |
| Radiological progression (±rising PSA) and no pain | 20 (17.4) | 14 (13.1) | 34 (15.3) |
| Pain status at study entry | 75 (65.2) | 74 (69.2) | 149 (67.1) |
| Missing | 9 (7.8) | 10 (9.3) | 19 (8.6) |
| Disease history | |||
| Metastatic (M1) disease at diagnosis, n (%) | 35 (30.4) | 41 (38.3) | 76 (34.2) |
| Gleason score 8–10 at diagnosis, n (%) | 63 (54.8) | 66 (61.7) | 129 (58.1) |
| Median duration of first ADT, months | 14.9 | 15 | 14.9 |
| Duration ≥12 months, n (%) | 67 (58.3) | 65 (60.7) | 132 (59.5) |
| Previous life extending therapy, n (%) | |||
| Docetaxel | 115 (100) | 107 (100) | 222 (100) |
| Abiraterone | 49 (42.6) | 54 (50.5) | 103 (46.4) |
| Enzalutamide | 65 (56.5) | 53 (49.5) | 118 (53.2) |
| Missing | 1 (0.9) | 0 | 1 (0.5) |
| Timing of androgen-signalling-targeted inhibitor before docetaxel, n (%) | 50 (43.5) | 48 (44.9) | 98 (44.1) |
| Median time from androgen-signalling-targeted inhibitor to progression, months | 8.0 | 7.1 | 7.6 |
| ≤6 months on first androgen-signalling-targeted inhibitor, n (%) | 56 (48.7) | 51 (47.7) | 107 (48.2) |
ADT, androgen deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; PSA, prostate-specific antigen.